Dabrafenib mesylate

Cat. No.: OB0225WX-2303

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Dabrafenib mesylate is an ATP-competitive B-Raf inhibitor characterized by IC50 values of 0.6 nM for the RafV600E mutant and 5.0 nM for c-Raf.

Synonym: GSK 2118436B; GSK2118436 Mesylate; 1195768-06-9; Dabrafenib (Mesylate); Taflinar; dabrafenib mesilate; GSK 2118436B; GSK-2118436B; Dabrafenib methanesulfonate; GSK2118436B; GSK-2118436 mesylate; GSK2118436 Methane sulfonate salt; N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; GSK2118436B, methane sulfonate salt; Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1); GSK2118436 Mesylate;GSK 2118436B; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate; MFCD20922872; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-thiazol-4-yl]-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide methanesulfonic acid; N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate

CAS No.: 1195768-06-9

Compound CID: 44516822

Formula: C₂₄H₂₄F₃N₅O₅S₃

Formula Weight: 615.67

Specification

Targets&IC50: Raf: 5 nM; B-Raf (V600E): 0.6 nM

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Dabrafenib mesylate is utilized in clinical pharmacology studies to examine the selective inhibition of V600-mutant BRAF kinases and the therapeutic modulation of metastatic neoplastic growth.